Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms?

Joo Hyun Lim, MD,*,1 Sang Gyun Kim, MD, PhD,*,1 Ji Won Kim, MD, PhD,2 Yoon Jin Choi, MD,1 Jieun Kwon, MD,1 Ji Yeon Kim, MD,1 Yun Bin Lee, MD,1 Jeongmin Choi, MD,1 Jong Pil Im, MD, PhD,1 Joo Sung Kim, MD, PhD,1 Hyun Chae Jung, MD, PhD,1 In Sung Song, MD, PhD1

Seoul, Korea

Background: It is rarely known whether antiplatelets increase the risk of bleeding after endoscopic submucosal dissection (ESD).

Objective: To evaluate the effect of antiplatelets on post-ESD bleeding.

Design: Retrospective study.

Setting: Single, tertiary-care referral center.

Patients: This study involved 1591 gastric neoplasms (815 adenomas and 776 early gastric cancers) in 1503 patients who had ESD between April 2005 and April 2010.

Intervention: ESD.

Main Outcome Measurements: Overt hematemesis/hematochezia, a drop of hemoglobin >2 g/dL from baseline, or requirement of endoscopic hemostasis, angiographic embolization, and/or transfusion.

Results: Of 1591 subjects, 274 took antiplatelets, among whom 102 discontinued them for 7 days or more before ESD. Post-ESD bleeding occurred in 94 subjects including 20 from the continuation group, 6 from the withdrawal group, and 68 from the no-antiplatelet group. In univariate analysis, antiplatelets, early gastric cancer (EGC), comorbidity, and specimen diameter were related to post-ESD bleeding. In multivariate analysis, EGC (odds ratio [OR] 1.839; 95% confidence interval [CI], 1.168-2.896; \(P = .009\)), comorbidity (OR 2.246; 95% CI, 1.280-3.939; \(P = .005\)), and specimen diameter (OR 2.315; 95% CI, 1.282-4.180; \(P = .005\)) were independent risk factors of post-ESD bleeding, whereas antiplatelet usage was not (OR 1.596; 95% CI, 0.877-2.903; \(P = .126\)). In subgroup analysis, continuous antiplatelet usage was not found to be an independent risk factor of post-ESD bleeding in multivariate analysis (OR 2.027; \(P = .146\)). Among 102 subjects who discontinued antiplatelets, 1 developed an acute cerebral infarction (1.0%).

Limitation: A retrospective, single-center analysis.

Conclusion: In ESD for antiplatelet users, continuous administration was not found to have an independent significant association with bleeding. (Gastrointest Endosc 2012;75:719-27.)

Currently, endoscopic submucosal dissection (ESD) is a widely used procedure as a curative treatment of gastric tumors, which preserves the stomach and allows 1-piece resection with tumor-free margins, even in cases of large and ulcerative lesions.1,2 As previously reported, the resection rate of complete en bloc ESD was over 80%, which was significantly better than that of conventional EMR.3 Despite its convenience and noninvasiveness, there is a
major concern about its bleeding complication. ESD has a greater risk of bleeding compared with ordinary EMR because of the larger resection diameter and depth. Thus, there have been efforts to find out ways to reduce post-ESD bleeding. Pantoprazole was found to be more effective than famotidine for the prevention of delayed bleeding after ESD in one study,1 and in another study, coagulating exposed vessels on the ulcer floor after ESD, which is known as post-ESD coagulation preventive therapy, reduced the risk for delayed bleeding.5 However, there are still bleeding concerns, and further measures are needed to prevent post-ESD bleeding.

The usage of antiplatelet agents increases as the incidence of cardiovascular disease increases. In the absence of a pre-existing bleeding disorder, endoscopic procedures can be performed on patients who take aspirin in standard doses.6 However, this is true only for ordinary procedures, and it is not yet known whether it applies to ESD.

The rate of post-ESD bleeding is reported to be 1.7% to 38%, based on the definition of bleeding.1,5,7,8 There have been controversies over the potential risk of post-ESD bleeding in antiplatelet users. In a retrospective study, tumor location, coagulator experience, and medicine potentially related to gastric injury/bleeding were revealed to be associated with a higher rate of post-ESD bleeding.9 Another study showed that resected specimen width of >40 mm was the only significant factor associated with delayed bleeding after ESD.10

In a previous guideline, it was recommended to discontinue antiplatelet agent therapy other than aspirin 7 to 10 days before high-risk endoscopic procedures, such as polypectomy, biliary sphincterotomy, pneumatic/bougie dilatation, percutaneous endoscopic gastrostomy placement, EUS-guided FNA, laser ablation/coagulation, or treatment of varices.11 However, this guideline had a recommendation about non-aspirin antiplatelet agents rather than aspirin for endoscopic procedures. A recently published guideline recommends discontinuation of all antiplatelet agents, including aspirin, before EMR or ESD, in case of low risk for a thrombotic event.12 However, this is a low-grade recommendation without results of large-scale trials, and there is no specific guideline for patients with high thrombotic risks. The aim of this study was to evaluate the effect of antiplatelet agents, including aspirin, on post-ESD bleeding and find evidence for whether or not to discontinue antiplatelet agents before ESD.

METHODS

Patients

A total of 1525 patients underwent ESD for 1613 gastric neoplasms, including 831 adenomas and 782 cases of early gastric cancer (ECG), at Seoul National University Hospital between April 2005 and April 2010. Endoscopic resection was performed entirely by ESD techniques, which were indicated if the following criteria were met: any lesions with low-grade to high-grade dysplasia, regardless of size, or well- to moderately differentiated adenocarcinoma confined to the mucosa ≤2 cm by endoscopic measurements without evidence of lymph node/distant metastases on abdominal CT/EUS. Ten subjects were excluded because of unclear medication history, and 12 patients were excluded because of anticoagulation before the procedure. Therefore, a total of 1591 lesions in 1503 patients, including 815 adenomas and 776 EGCs, were reviewed retrospectively (Fig. 1).

Gastric adenoma was defined as intraepithelial neoplasia of category 3 or 4 in the revised Vienna classification, including epithelial dysplasia regardless of mucosal elevation, and EGC was defined as invasive carcinoma of category 5.13 Antiplatelet agents were defined as drugs that decrease platelet aggregation or inhibit thrombus formation as follows: cyclooxygenase inhibitors like aspirin, phosphodiesterase inhibitors like cilostazol, adenosine diphosphate receptor inhibitors like clopidogrel or ticlopidine, and 5 HT2 antagonists like sarpogrelate.

We used the terminology of subject for each lesion treated with one ESD procedure. When there were two specimens resected from one ESD procedure, it was counted as one subject, and the diameter of the larger specimen was taken for analysis.

This study was approved by the Institutional Review Board of the Seoul National University Hospital. Patient consent was waived, given the retrospective nature of this study.

Procedures

ESD was performed with patients under sedation with intravenous midazolam by using an insulation-tipped knife (Kachu Tech, Seoul, Korea) through a standard single-channel endoscope (Olympus H260; Olympus Optical Co, Tokyo, Japan) by a single experienced endoscopist (S.G.K). After the chromoendoscopic observation with indigo carmine, we placed marking dots 5 mm outside the tumor margin by using a needle-knife (KD-11; Olympus) with a forced 20-W coagulation current (VIO 300D; Erbe, Tübingen, Germany). Then a mixture of normal saline solution and indigo carmine with diluted epinephrine (1:100,000) was injected into the submucosal layer along with the marking dots to make the submucosal cushion

Take-home Message

- Continuous administration of antiplatelets does not seem to increase bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasms.
- These results are important because ESD can be acceptable without the discontinuation of antiplatelet agents for patients who cannot interrupt antiplatelet agent therapy because of high cardiovascular risks.
beneath the lesion. After a small initial incision was made with the needle-knife, a circumferential mucosal incision was made around the marking dots, and the submucosal layer was dissected by using the insulation-tipped-knife in 80-W endocut mode. Hemostasis was performed for bleeding spots or visible vessels with a coagrasper (MTN-BF-2; Standard Sci. tech, Seoul, Korea). All of the patients were administered proton pump inhibitors intravenously the day of the procedure and were discharged with oral proton pump inhibitor treatment for 4 weeks on the next day when there were no signs of bleeding. In cases of overt bleeding after discharge, the patients were educated to call the hospital and visit the emergency department immediately. After 2 weeks from discharge, all of the patients visited the outpatient department to confirm the final pathologic results, when the clinical assessment of complete resection and delayed bleeding was made.

**Data analysis**

All subjects were grouped into one of the following groups: no-antiplatelet group, continuation group, and withdrawal group. Patients who had continued antiplatelet therapy or had it interrupted <7 days before ESD were counted as continuous users, and those who had never used antiplatelet therapy or had it discontinued 30 days or more before the procedure were counted as non-users. Others were counted in the withdrawal group. Post-ESD bleeding was defined as an episode of any of the following: overt hematemesis/hematochezia; a drop of hemoglobin >2 g/dL; or requirement of endoscopic hemostasis or angiographic embolization and/or transfusion. Early bleeding was defined as a bleeding episode within 72 hours after ESD, and delayed bleeding was defined as such beyond 72 hours after ESD.

To investigate the potential risk factors that influence post-ESD bleeding, the following variables were analyzed; age (<65 or ≥65 years), sex, comorbidity that may affect bleeding or coagulation (cardiovascular disease, liver cirrhosis, chronic renal failure, or hematologic disease), coagulation abnormality, pathologic diagnosis of the lesion (adenoma or EGC), the diameter of the resected specimen (<4 cm or ≥4 cm), location (upper, middle, or lower third), and status of antiplatelet therapy (no antiplatelets, continuation, or withdrawal).

We used the cut-off value of 4 cm for the specimen diameter, taking into account a previous study that showed that size larger than 4 cm was a risk factor for post-ESD bleeding.

**Statistical analysis**

Although some of the patients had more than one procedure, and some procedures involved more than one specimen, the different subject data quantities observed were assumed to constitute statistically independent observations for the purposes of statistical analysis. Categorical variables were compared by using the chi-square test and Fisher exact test for univariate analysis. Those variables with $P < .200$ in the univariate analyses and some of their interactions were examined in multivariate binary logistic regression models. A $P$ value <.05 was considered significant. The $P$ values for the univariate statistical tests were not corrected for multiple testing, because those tests were taken as exploratory. The subsequent multivariate logistic regression analyses were considered the main definitive results because they determined those variables independently associated with bleeding, after we adjusted for the contributions of the other variables. Because there was a second multivariate modeling of usage subgroups, it is noted that correction by the Bonferroni method would not have removed statistical significance from any of the multivariate findings. All $P$ values were presented uncorrected for multiple testing. All of the analyses were performed with the Statistical Package for the Social Sciences, version 18.0 for Windows (SPSS, Chicago, IL).
RESULTS

Among a total of 1591 subjects, 274 took antiplatelet agents, among whom 102 discontinued therapy for 7 days or more before ESD. Thus, there were 1371 subjects in the no-antiplatelet group, 102 in the withdrawal group, and 172 in the continuation group.

The mean age of each group presented a linear tendency of older age among the antiplatelet users, with statistical significance ($P < .001$) (Table 1). The male proportion was 70.1% in the no-antiplatelet group, whereas that was larger in the withdrawal group and continuation group, with 83.3% and 78.5%, respectively ($P < .003$). Also, antiplatelet users had a greater rate of comorbidities (4.8% in the no-antiplatelet group, 34.3% in the withdrawal group, and 50.6% in the continuation group; $P < .001$). Coagulation abnormality was rare in all 3 groups, without significant differences among them. Also, there were no significant differences among the groups in terms of the carcinoma rate, specimen diameter, and location of the tumor. Antiplatelet users were taking either 1 or a combination of 2 among 5 kinds of antiplatelets. Aspirin users made up the biggest proportion, 77.0%, followed by 7.3% for dual antiplatelet users with aspirin and clopidogrel (Table 2).

Among 1591 subjects, 94 bleeding events occurred (5.9%). All of the episodes of bleeding were well-controlled with endoscopic hemostasis or angiographic embolization when endoscopic hemostasis failed. Angiographic embolization was performed in 3 subjects. There were no perforations or deaths related to ESD. Twenty of the bleeding episodes occurred in the continuation group (11.6%), 6 in the withdrawal group (5.9%), and 68 in the no-antiplatelet group (5.2%), which showed a relationship between major bleeding and antiplatelet use ($P < .001$) (Fig. 1). In terms of the time of bleeding, 13 episodes were delayed bleeding (13.8%), including 4 in the continuation group (2.3%), 9 in the no-antiplatelet group (0.7%), and 0 in the withdrawal group, with near significance at $P = .061$. However, early bleeding episodes occurred in 16 from the continuation group (9.3%), 6 in the withdrawal group (5.9%), and 59 in the

**TABLE 1. Baseline characteristics**

<table>
<thead>
<tr>
<th></th>
<th>No-antiplatelet group (n = 1317)</th>
<th>Withdrawal group (n = 102)</th>
<th>Continuation group (n = 172)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>61.61 (9.321)</td>
<td>66.45 (7.341)</td>
<td>67.60 (7.807)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age ≥ 65 years</td>
<td>541 (41.1)</td>
<td>64 (62.7)</td>
<td>120 (69.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Male sex, no. (%)</td>
<td>923 (70.1)</td>
<td>85 (83.3)</td>
<td>135 (78.5)</td>
<td>.003</td>
</tr>
<tr>
<td>Comorbidity, no. (%)*</td>
<td>63 (4.8)</td>
<td>35 (34.3)</td>
<td>87 (50.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Coagulation abnormality, no. (%)†</td>
<td>14 (1.2)</td>
<td>0 (0.0)</td>
<td>2 (1.4)</td>
<td>.907</td>
</tr>
<tr>
<td>Carcinoma, no. (%)</td>
<td>628 (47.7)</td>
<td>59 (57.8)</td>
<td>89 (51.7)</td>
<td>.131</td>
</tr>
<tr>
<td>Specimen diameter, mean (SD), cm</td>
<td>4.55 (1.391)</td>
<td>4.59 (1.125)</td>
<td>4.78 (1.502)</td>
<td>.110</td>
</tr>
<tr>
<td>Specimen diameter ≥ 4 cm, no. (%)</td>
<td>880 (67.4)</td>
<td>71 (70.3)</td>
<td>128 (74.4)</td>
<td>.160</td>
</tr>
<tr>
<td>Tumor location, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td>.327</td>
</tr>
<tr>
<td>Upper</td>
<td>116 (8.8)</td>
<td>15 (14.7)</td>
<td>20 (11.6)</td>
<td></td>
</tr>
<tr>
<td>Middle</td>
<td>428 (32.5)</td>
<td>21 (20.6)</td>
<td>56 (32.6)</td>
<td></td>
</tr>
<tr>
<td>Lower</td>
<td>773 (58.7)</td>
<td>66 (64.7)</td>
<td>96 (55.8)</td>
<td></td>
</tr>
<tr>
<td>SD, Standard deviation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
*Comorbidity denotes cardiovascular disease, liver cirrhosis, chronic renal failure, or hematologic disease.
†Coagulation abnormality was defined as a partial thromboplastin or prothrombin time value above the normal value, a platelet count of <100,000/mm$^3$.

**TABLE 2. Type of antiplatelets**

<table>
<thead>
<tr>
<th></th>
<th>No.</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>211</td>
<td>77.0</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>19</td>
<td>6.9</td>
</tr>
<tr>
<td>Cilostazol</td>
<td>8</td>
<td>2.9</td>
</tr>
<tr>
<td>Triflusal</td>
<td>6</td>
<td>2.2</td>
</tr>
<tr>
<td>Sarpogrelate</td>
<td>2</td>
<td>0.7</td>
</tr>
<tr>
<td>Aspirin + clopidogrel</td>
<td>20</td>
<td>7.3</td>
</tr>
<tr>
<td>Aspirin + cilostazol</td>
<td>2</td>
<td>0.7</td>
</tr>
<tr>
<td>Aspirin + triflusal</td>
<td>2</td>
<td>0.7</td>
</tr>
<tr>
<td>Aspirin + sarpogrelate</td>
<td>3</td>
<td>1.1</td>
</tr>
<tr>
<td>Clopidogrel + sarpogrelate</td>
<td>1</td>
<td>0.4</td>
</tr>
</tbody>
</table>
no-antiplatelet group (4.5%), which showed a linear tendency of early bleeding among antiplatelet users \((P = 0.007)\). Univariate analysis showed that the diagnosis of carcinoma, comorbidity that may affect coagulation activity, the diameter of the resected specimen, and uninterrupted antiplatelet usage were related to post-ESD bleeding, with statistical significance (Table 3). In multivariate analysis, however, the diagnosis of carcinoma, comorbidity, and specimen diameter were revealed to be independent risk factors for post-ESD bleeding, whereas uninterrupted antiplatelet usage was not (Table 4).

We performed subgroup analysis among the subjects under antiplatelet therapy, regardless of whether interrupted or not, to evaluate the effect of continuous administration on post-ESD bleeding. In univariate analysis, specimen diameter and uninterrupted antiplatelet therapy showed \(P\) values < .200 (Table 5); however, none of them were revealed to be independent risk factors of post-ESD bleeding in multivariate analysis (Table 6).

Among continuous antiplatelet users, there were no significant differences in bleeding rates among single aspirin users, non-aspirin antiplatelet users, and combination users of aspirin with non-aspirin antiplatelets \((P = .404)\). At the same time, no significant differences in specimen diameters were found among these 3 groups \((P = .089)\). When comparing single aspirin users and single non-aspirin antiplatelet users, there were no significant differences in bleeding rates \((P = .360)\). Clopidogrel, known to be more potent than low-dose aspirin, did not show more risk of bleeding, compared with aspirin alone (5.6% vs 13.8%; \(P = .468\)). In subgroup analysis among single aspirin users, regardless of whether therapy was interrupted or not, specimen diameter \((OR 8.000; P = .019)\), location of the lesion \((P = .130)\), and continuous aspirin usage \((OR 2.880; P = .039)\) were related to post-ESD bleeding in univariate analysis (Table 7). However, in multivariate analysis, none of them were independent risk factors of post-ESD bleeding \((OR 7.057; CI, 0.913-54.533; P = .061; P = .929); and OR 2.009; 95% CI, 0.900-7.567; P = .078, respectively\) (Table 8). In this analysis, specimen diameter showed an OR well above 1.00 but had such wide 95% CIs that there was nonsignificance. This is assumed to be because of the small number of subjects included in this subgroup.

In respect to the time of bleeding, specific analyses for early and delayed bleeding were performed separately. In univariate analysis for early bleeding, comorbidity, the diagnosis of carcinoma, specimen diameter, and uninterrupted antiplatelet usage were revealed to be related to early bleeding, which was the same as in analysis for overall post-ESD bleeding. However, multivariate analysis for early bleeding showed that comorbidity \((OR 2.429; 95% CI, 1.339-4.406; P = .003)\), carcinoma \((OR 1.756; 95% CI, 1.081-2.854; P = .023)\), and specimen diameter \((OR 2.593; 95% CI, 1.344-5.003; P = .001)\) were independent risk factors for early post-ESD bleeding.
(45x295) were independent risk factors of early bleeding, whereas uninterrupted antiplatelet usage was not (OR 1.363; 95% CI, 0.709-2.621; P = .353). For delayed bleeding, univariate analysis failed to clarify any risk factors. Univariate analysis for early bleeding among the subgroup of antiplatelet users showed that specimen diameter was the only variable related to early bleeding (OR 4.777; P = .047), whereas uninterrupted administration of antiplatelets was not (OR 1.057; P = .314). Among single aspirin users, univariate analysis showed a relationship between specimen diameter and early bleeding (OR 6.652; P = .047), but continuous aspirin usage showed no relationship with early bleeding (OR 2.272; P = .124). Of 102 patients who discontinued antiplatelets before ESD, 1 developed an acute cerebral infarction during the withdrawal period (1.0%).

**DISCUSSION**

Currently, ESD is one of the most commonly performed procedures for early gastric neoplasms. At the same time, the number of antiplatelet users has been growing with the increase of cardiovascular diseases. Especially, there are patients who cannot interrupt antiplatelet agents because of high thromboembolic risks, such as those who have recently undergone coronary stent insertion. There are no published trials primarily dealing with the effects of antiplatelets, including aspirin, on post-ESD bleeding except for few expert opinions. Therefore, this study was designed to find out whether antiplatelet agents increase post-ESD bleeding, so that we can establish a guideline for antiplatelet users in high-risk endoscopic procedures.

Previous guidelines for antiplatelets in endoscopic procedures have classified procedural and patients’ risks into low and high.6,11 In a high-risk procedure such as EMR, antiplatelets are generally recommended to be discontinued to prevent bleeding, but whether this can be applied to single aspirin use is controversial. Most Western endoscopists did not recommend that single aspirin users stop taking aspirin but suggested that patients taking non-aspirin antiplatelets discontinue therapy for more than a week before endoscopic polypectomy. Meanwhile, Eastern endoscopists recommended that their patients discontinue both of the medications for more than a week.14,15 Recently, the European Society of Gastrointestinal Endoscopy published a guideline for endoscopy and antiplatelet agents, which recommended discontinuation of any antiplatelet agents, including aspirin, for EMR and ESD, provided that the patient was not at high risk for a thrombotic event.12 However, this recommendation was based on a low level of evidence from a retrospective study that showed that use of “drugs potentially related to gastric injury/bleeding” (ie, aspirin, nonsteroidal anti-inflammatory drugs, anticoagulants, and corticosteroids) was associated with an increased risk of post-ESD bleeding.9 It did not distinguish
antiplatelets from anticoagulants and did not evaluate the effect of continuous administration of the drugs compared with that of interruption of therapy.

ESD has a potential of a higher risk of postprocedural bleeding compared with conventional EMR or polypectomy because of the larger and deeper resection. Antiplatelets can augment the risk of bleeding after ESD, but unconditional discontinuation also can augment the risk of cardiovascular events by thromboembolism in high-risk patients. In this study, a massive cerebral infarction developed in a patient with atrial fibrillation after discontinuation of aspirin for 5 days.

This study revealed that comorbidity, the pathologic diagnosis of carcinoma, and the size of the resected specimen were independent risk factors for post-ESD bleeding. In this study, a massive cerebral infarction developed in a patient with atrial fibrillation after discontinuation of aspirin for 5 days.

This study revealed that comorbidity, the pathologic diagnosis of carcinoma, and the size of the resected specimen were independent risk factors for post-ESD bleeding. This suggests that it is essential to achieve meticulous prophylactic hemostasis for large lesions.

Our study showed that uninterrupted antiplatelet therapy was not related to higher bleeding risks independently, even in ESD, which is known as a higher risk procedure than EMR. Continuous administration was not an independent risk factor for bleeding among antiplatelet users. This is an important finding for those who cannot discontinue the administration of antiplatelets, especially single aspirin, because of high cardiovascular risks.

In regard to the type of antiplatelets, there were no significant differences in bleeding risks between single aspirin users and non-aspirin users. Also, clopidogrel, a novel antiplatelet agent known to be more potent than conventional antiplatelets, did not show more risk of bleeding than single aspirin in this study. However, this should be further evaluated with more patients taking clopidogrel.

Like previous studies, this study showed that the size of the resected specimen was related to post-ESD bleeding. This suggests that it is essential to achieve meticulous prophylactic hemostasis for large lesions.

Our study showed that uninterrupted antiplatelet therapy was not related to higher bleeding risks independently, even in ESD, which is known as a higher risk procedure than EMR. Continuous administration was not an independent risk factor for bleeding among antiplatelet users. This is an important finding for those who cannot discontinue the administration of antiplatelets, especially single aspirin, because of high cardiovascular risks.

In regard to the type of antiplatelets, there were no significant differences in bleeding risks between single aspirin users and non-aspirin users. Also, clopidogrel, a novel antiplatelet agent known to be more potent than conventional antiplatelets, did not show more risk of bleeding than single aspirin in this study. However, this should be further evaluated with more patients taking clopidogrel.

When known to be under anticoagulation, patients were recommended to discontinue it for more than 5 days before the procedure. On the other hand, no recommendations for discontinuation were given by the physicians for antiplatelet therapy. Nevertheless, some patients discontinued antiplatelet therapy voluntarily for various du-
Statistical significance was not found (larger specimens among these patients, even though statistical significance was not found \((P = .069)\). Uninterrupted antiplatelet therapy did not show significant risk when these factors were excluded in multivariate analysis. Thus, its independent risk is thought to be inconsiderable.

In terms of the time of bleeding, the results for early bleeding were similar to those of overall bleeding. However, no variables were revealed to be risk factors of delayed bleeding in this study. Unlike in the previous study, which showed that early bleeding is an independent risk factor of delayed bleeding, each of the events occurred exclusively in this study.

So far, endoscopic procedures have been improved, and their uses have been broadened continuously. As the use of these procedures grew, studies suggested that endoscopic procedures such as sphincterotomy, polypectomy, or biopsy could be performed without interrupting therapy with aspirin or other nonsteroidal anti-inflammatory drugs. On the other hand, there are opinions recommending avoiding high-risk endoscopic procedures while dual antiplatelet therapy is needed after percutaneous coronary intervention with stent placement. The result of our study suggests that continuous antiplatelet therapy would not increase the bleeding risk in ESD. However, considering that those who are taking antiplatelets carry more comorbidities, ESD should be done more carefully in this group.

There are several limitations to this study. One is that it is a retrospective review from a single center. However, it has an advantage of a large number of subjects. Also, there are the problems of model instability and the small (<20%) proportion of subjects with antiplatelet usage. Another limitation is that the types and dosages of antiplatelets were not clarified. There is a possibility of various risks of bleeding depending on the different types and dosages of antiplatelets. Also, there is the possibility that patients who did not interrupt antiplatelet therapy had more thrombotic risks than patients in the withdrawal group. This might have affected the result of less bleeding in continuous users, which should be further evaluated in a prospective, randomized trial.

In conclusion, this study suggests that patients on antiplatelet therapy because of high cardiovascular risks may undergo ESD without increased risks of post-ESD bleeding. Prospective, randomized studies are mandatory for those who are at high cardiovascular risks to decide whether or not to interrupt antiplatelet therapy before ESD for gastric neoplasms.

REFERENCES